Johan Rojas Suspended 80 Games Following Positive Test for Boldenone

Philadelphia Phillies outfielder Johan Rojas will forfeit $395,305 and miss 80 games after an independent arbitrator upheld a PED suspension for Boldenone.

Major League Baseball announced on Monday that Philadelphia Phillies outfielder Johan Rojas has been issued an 80-game suspension without pay. This disciplinary action stems from a positive test for Boldenone, a performance-enhancing substance prohibited under the Joint Drug Prevention and Treatment Program. Independent arbitrator Martin F. Scheinman upheld the penalty after denying a grievance filed by the Major League Baseball Players Association. Consequently, the 25-year-old will be sidelined for approximately 43% of the 187-day regular season, with a projected return date of June 25, assuming no schedule disruptions occur.

The financial impact of this Johan Rojas suspension is substantial, totaling a loss of $395,305 in salary. His current contract structure dictates a $803,500 salary at the major league level and $321,826 while assigned to the minor leagues. Beyond the immediate loss of earnings and playing time, the outfielder faces a long-term postseason restriction. Under league rules, any player testing positive for a PED is ineligible for the playoffs during the year of the infraction; however, due to the timing of this ruling, Rojas is specifically barred from participating in the 2026 postseason.

Statistically, Rojas enters this forced hiatus following a 2023 campaign where he appeared in 114 games for Philadelphia. During that season, he posted a .224 batting average, contributing one home run, 18 RBIs, and 12 stolen bases. His performance led to a demotion to Triple-A Lehigh Valley on August 1, after which he did not return to the major league roster for the remainder of the year. Over a career spanning 250 games, the outfielder has maintained a .252 lifetime average with 73 runs batted in and 51 successful stolen base attempts in 62 tries.

During the current spring training session, the Dominican-born player recorded three hits across 15 at-bats, including a single RBI. His preparation for the season was already altered when he was removed from the Dominican Republic’s World Baseball Classic roster prior to the tournament's commencement. The Phillies organization released a formal statement expressing disappointment regarding the violation but reiterated their commitment to the league's drug prevention protocols. This vacancy in the outfield depth chart forces the front office to reevaluate their bench options for the first 92 days of the calendar.

Rojas becomes the third Major League player disciplined for a drug violation in the current calendar year. He joins free agent outfielder Max Kepler, who received an 80-game ban on January 9 for Epitrenbolone, and Atlanta outfielder Jurickson Profar, who was suspended for the entire season on March 3. Profar’s case involved a second offense related to exogenous testosterone and its metabolites. Across all levels of professional baseball, Rojas represents the sixth individual to be sanctioned for PED use since the start of the year.

The enforcement of the 80-game ban highlights the rigorous testing conducted by the league's office in New York. Boldenone, the specific anabolic steroid detected in the sample, is a synthetic derivative of testosterone. The denial of the appeal by Scheinman ensures that the clock on the suspension begins immediately with the start of the regular season. This timeline removes a significant speed threat from the Phillies' lineup, as Rojas has averaged a stolen base every five games throughout his professional tenure.

In terms of roster management, the Phillies must now navigate the first half of the 162-game schedule without their primary defensive substitute. The loss of 12 steals from the previous season creates a void in the team's small-ball strategy. Furthermore, the 2026 playoff eligibility restriction serves as a lingering consequence that affects the franchise's long-term October planning. The outfielder will be permitted to participate in extended spring training and minor league rehabilitation assignments toward the end of his ban to prepare for the June 25 reinstatement.

This ruling marks a pivotal moment in the career of the young outfielder, who was expected to compete for a more permanent role in the grass. Instead, the focus shifts to his eventual return to the Lehigh Valley affiliate or the Philadelphia bench in late June. The $395,305 forfeiture represents nearly half of his potential earnings, reflecting the severity of the Joint Drug Agreement's penalties for first-time offenders. As the Phillies move forward, the internal competition for the remaining outfield spots will intensify during the final weeks of camp.

MLB's drug prevention program continues to utilize independent arbitration to finalize these cases, ensuring a standardized process for all 30 clubs. The specific mention of Boldenone in the official report aligns with the league's efforts to maintain transparency regarding banned substances. With Rojas unavailable until the summer solstice, the Philadelphia coaching staff will likely lean on veteran depth to bridge the gap in center and right field. The 25-year-old’s absence will be felt most acutely in late-inning defensive situations where his range has historically been a metric leader for the club.